Comparative Pharmacology
Head-to-head clinical analysis: NEPHROSCAN versus TECHNESCAN GLUCEPTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROSCAN versus TECHNESCAN GLUCEPTATE.
NEPHROSCAN vs TECHNESCAN GLUCEPTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Technetium-99m glucepstate is a radiopharmaceutical that localizes in renal cortex and urinary tract via glomerular filtration and tubular secretion. In the brain, it accumulates in areas of disrupted blood-brain barrier, such as tumors, infarcts, or abscesses, due to increased vascular permeability and binding to intracellular components.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
For brain imaging: 555-740 MBq (15-20 mCi) intravenously, single dose. For kidney imaging: 111-370 MBq (3-10 mCi) intravenously, single dose.
None Documented
None Documented
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2-4 hours; allows rapid renal clearance and minimal background interference for imaging.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Renal: >90% of injected dose excreted via glomerular filtration within 24 hours; biliary/fecal: <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical